Abstract
Nanoparticles (NPs) have emerged as versatile platforms in cancer immunotherapy, offering targeted delivery, immune modulation, and improved safety profiles. These nanoscale materials can be engineered to co-deliver tumor antigens, adjuvants, and checkpoint inhibitors, thereby enhancing immune system activation against malignant cells. This review explores recent advances in nanoparticle-based immunotherapeutic strategies, highlighting their ability to overcome biological barriers, enhance antigen presentation, and reduce off-target effects. Despite significant progress, challenges remain concerning nanoparticle biodistribution, immunotoxicity, regulatory approval, and scalability. Addressing these barriers through rational design and translational research will be critical in achieving clinical success for nanoparticle-driven cancer immunotherapies.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.